Drug Type Small molecule drug |
Synonyms LCB-03-0110, LCB-03-110, LCB03-0110 |
Action inhibitors, antagonists |
Mechanism CSK inhibitors(C-terminal Src kinase inhibitors), DDR1 antagonists(Discoidin domain receptor 1 antagonists), JAK inhibitors(Janus kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H23N3O2S |
InChIKeyZCWXCBKGPJOAFQ-UHFFFAOYSA-N |
CAS Registry1228102-01-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Xerophthalmia | Preclinical | South Korea | 14 Nov 2024 | |
Neoplasms | Preclinical | South Korea | 27 Apr 2015 | |
Neoplasms | Preclinical | South Korea | 27 Apr 2015 | |
Neurodegenerative Diseases | Preclinical | United States | - |